A Phase 1 interventional study of [14C]-LY3473329 and [14C]-LY3473329 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to male participants aged 35 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-30.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to evaluate how much of the study drug (LY3473329), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into urine, feces and expired air in healthy male participants. The study will also measure how much of the study drug gets into the bloodstream when taken orally, compared to when injected directly into the vein, how its broken down, and how long it takes the body to get rid of it. The study is conducted in two parts. The study will last up to approximately 9 and 7 weeks for part 1 and 2, respectively.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of \[¹⁴C\]-LY3473329 administered orally
Drug: [14C]-LY3473329
Single dose of LY3473329 administered orally followed by a single dose of \[¹⁴C\]-LY3473329 administered intravenously (IV)
Drug: [14C]-LY3473329 · Drug: LY3473329
Administered orally
Administered IV
Administered orally
Part 1: Urinary Excretion of LY3473329 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Part 1: Urinary Excretion of LY3473329 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Time frame: Day 1 up to Day 29 post dose
Part 1: Fecal Excretion of LY3473329 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Part 1: Fecal Excretion of LY3473329 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Time frame: Day 1 up to Day 29 post dose
Part 2: Pharmacokinetics (PK): Absolute bioavailability (F) of LY3473329
Part 2: PK: F of LY3473329
Time frame: Day 1 up to Day 9 post dose
Part 1: PK: Area Under the Curve Concentration Versus Time Curve From Time zero to Last Time Point (AUC[0-tlast]) of LY3473329
Part 1: PK: AUC(0-tlast) of LY3473329
Time frame: Day 1 up to Day 29 post dose
Part 1: PK: Area Under the Curve Concentration Versus Time Curve From Time zero to Last Time Point (AUC[0-tlast]) of Total Radioactivity
Part 1: PK: AUC(0-tlast) of Total Radioactivity
Time frame: Day 1 up to Day 29 post dose
Part 1: PK: Area Under the Curve Concentration Versus Time Curve From Time zero to Infinity (AUC[0-∞) of LY3473329
Part 1: PK: AUC(0-∞) of LY3473329
Time frame: Day 1 up to Day 29 post dose
Part 1: PK: Area Under the Curve Concentration Versus Time Curve From Time zero to Infinity (AUC[0-∞) of Total Radioactivity
Part 1: PK: AUC(0-∞) of Total Radioactivity
Time frame: Day 1 up to Day 29 post dose
Part 1: PK: Maximum Concentration (Cmax) of LY3473329
Part 1: PK: Cmax of LY3473329
Time frame: Day 1 up to Day 29 post dose
Part 1: PK: Maximum Concentration (Cmax) of Total Radioactivity
Part 1: PK: Cmax of Total Radioactivity
Time frame: Day 1 up to Day 29 post dose
Part 1: Total Radioactivity Recovered in Urine, Feces, and Expired Air (if applicable)
Part 1: Total Radioactivity Recovered in Urine, Feces, and Expired Air (if applicable)
Time frame: Day 1 up to Day 29 post dose
Part 1: Total Number of Metabolites of LY3473329
Part 1: Total Number of Metabolites of LY3473329
Time frame: Day 1 up to Day 29 post dose
Part 2: PK: AUC (0-∞) of LY3473329
Part 2: PK: AUC (0-∞) of LY3473329
Time frame: Day 1 up to Day 9 post dose
Part 2: PK: AUC (0-∞) of [14C]-LY3473329
Part 2: PK: AUC (0-∞) of \[14C\]-LY3473329
Time frame: Day 1 up to Day 9 post dose
Part 2: PK: AUC (0-∞) of Total Radioactivity
Part 2: PK: AUC (0-∞) of Total Radioactivity
Time frame: Day 1 up to Day 9 post dose
Part 2: PK: Cmax of LY3473329
Part 2: PK: Cmax of LY3473329
Time frame: Day 1 up to Day 9 post dose
Part 2: PK: Cmax of [14C]-LY3473329
Part 2: PK: Cmax of \[14C\]-LY3473329
Time frame: Day 1 up to Day 9 post dose
Part 2: PK: Cmax of Total Radioactivity
Part 2: PK: Cmax of Total Radioactivity
Time frame: Day 1 up to Day 9 post dose
Part 2: Total Radioactivity Recovered in Urine and Feces
Part 2: Total Radioactivity Recovered in Urine and Feces
Time frame: Day 1 up to Day 9 post dose
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2024 to primary completion in May 2024, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Muvalaplin